Protocol for Researching the Alpha Stack:
BPC-157 / TB-500 – For research purposes only, 7 sprays daily.
AOD-9604 – For research purposes only, 7 sprays daily.
PT-141 – For research purposes only, 7 sprays prior to activity.
BPC-157
BPC-157 (also known as PL 14736) is a pentadecapeptide. It has the amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. This peptide has a molecular formula of C62H98N16O22. The PUBCHEM ID is CID 9941957.
There are some tentative pre-clinical studies on animals and in vitro suggesting possible benefit in wound healing and bowel disorders although all of these studies come from a single research group.
TB-500
Work with cell cultures and experiments with animals have shown that administration of thymosin β4 can promote migration of cells, formation of blood vessels, maturation of stem cells, survival of various cell types and lowering of the production of pro-inflammatory cytokines. These multiple properties have provided the impetus for a worldwide series of on-going clinical trials of potential effectiveness of thymosin β4 in promoting repair of wounds in skin, cornea and heart.
Such tissue-regenerating properties of thymosin β4 may ultimately contribute to repair of human heart muscle damaged by heart disease and heart attack. In mice, administration of thymosin β4 has been shown to stimulate formation of new heart muscle cells from otherwise inactive precursor cells present in the outer lining of adult hearts, to induce migration of these cells into heart muscle and recruit new blood vessels within the muscle.
PT-141
Bremelanotide, sold under the brand name Vyleesi, is a medication used to treat low sexual desire in women. Specifically it is used for low sexual desire which occurs before menopause and is not due to medical problems, psychiatric problems, or problems within the relationship. It is given by an injection just under the skin of the thigh or abdomen.
Common side effects include nausea, pain at the site of injection, and headache. It may also cause a temporary increase in blood pressure and decrease in heart rate after each dose, and darkening of the gums, face, and breasts. The medication is a peptide and acts by activating the melanocortin receptors.
Bremelanotide was approved for medical use in the United States in 2019. It was developed by Palatin Technologies. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
